Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 15;208(6):737-739.
doi: 10.1164/rccm.202304-0716LE.

Prostaglandin I2 Therapy Promotes Regulatory T Cell Generation in Patients with Pulmonary Arterial Hypertension

Allison E Norlander  1   2   3 , Masako Abney  1 , Jacqueline-Yvonne Cephus  1 , Caroline E Roe  4 , Jonathan M Irish  4 , Nicholas J Shelburne  1 , Dawn C Newcomb  1 , Anna R Hemnes  1 , R Stokes Peebles Jr  1   4   5
Affiliations

Prostaglandin I2 Therapy Promotes Regulatory T Cell Generation in Patients with Pulmonary Arterial Hypertension

Allison E Norlander et al. Am J Respir Crit Care Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Prostaglandin I2 (PGI2) signaling promotes regulatory T cell (Treg) polarization in participants treated with a PGI2 analog for pulmonary arterial hypertension (PAH). Blue circles indicate participants with IPAH, red squares indicate participants with SPAH, black triangles indicate participants with HPAH. (A) Treg percentage in all participants. (B) Mean fluorescence intensity (MFI) (geometric mean) of Foxp3 within Tregs in all participants. (C) MFI (geometric mean) of CD44 within Tregs in all participants. (D) T effector cell (Teff):Treg ratio in all participants. Statistical significance was determined by paired t test. *P < 0.05 and **P < 0.01. HPAH = heritable PAH; IPAH = idiopathic PAH; SPAH = scleroderma PAH.
See this image and copyright information in PMC

References

    1. Thenappan T, Ormiston ML, Ryan JJ, Archer SL. Pulmonary arterial hypertension: pathogenesis and clinical management. BMJ . 2018;360:j5492. - PMC - PubMed
    1. Thompson AAR, Lawrie A. Targeting vascular remodeling to treat pulmonary arterial hypertension. Trends Mol Med . 2017;23:31–45. - PubMed
    1. Voelkel NF, Tamosiuniene R, Nicolls MR. Challenges and opportunities in treating inflammation associated with pulmonary hypertension. Expert Rev Cardiovasc Ther . 2016;14:939–951. - PMC - PubMed
    1. Steiner MK, Syrkina OL, Kolliputi N, Mark EJ, Hales CA, Waxman AB. Interleukin-6 overexpression induces pulmonary hypertension. Circ Res . 2009;104:236–244. - PMC - PubMed
    1. Luger D, Silver PB, Tang J, Cua D, Chen Z, Iwakura Y, et al. Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. J Exp Med . 2008;205:799–810. - PMC - PubMed

Publication types

MeSH terms